¶ published: true
tags: kind:mechanism, section:mechanisms, state:published, evidence:strong
editor: markdown
pageId: 15242
dateCreated: "2026-03-19T13:44:19.122Z"
dateUpdated: "2026-04-01T14:00:00.000Z"
lastReviewed: "2026-04-01T14:00:00.000Z"
refs:
heneka2018:
authors: Heneka MT, et al.
title: Neuroinflammation in Parkinson's disease
journal: Lancet Neurology
year: 2018
doi: 10.1016/S2213-2600(18)30069-2
pmid: 29371075
streit2012:
authors: Streit WJ, et al.
title: 'Microglial pathology: I. When microglia go bad'
journal: Progress in Neurobiology
year: 2012
doi: 10.1016/j.pneurobio.2012.05.001
kim2015:
authors: Kim C, et al.
title: Antagonizing neural toll-like receptor 2 prevents synucleinopathy by activating autophagy
journal: Cell Reports
year: 2015
doi: 10.1016/j.celrep.2015.03.017
george2013:
authors: George S, et al.
title: 'α-Synuclein: The long distance runner'
journal: Annals of Neurology
year: 2013
doi: 10.1002/ana.24723
gordon2018:
authors: Gordon R, et al.
title: Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice
journal: Nature Medicine
year: 2018
doi: 10.1038/s41591-018-0053-5
liddelow2017:
authors: Liddelow SA, et al.
title: Neurotoxic reactive astrocytes are induced by activated microglia
journal: Nature
year: 2017
doi: 10.1038/nature21029
sulzer2017:
authors: Sulzer D, et al.
title: T cells from patients with Parkinson's disease recognize α-synuclein peptides
journal: Nature
year: 2017
doi: 10.1038/nature22815
gray2013:
authors: Gray MT, Woulfe JM
title: Striatal blood-brain barrier permeability in Parkinson's disease
journal: Acta Neuropathol Commun
year: 2013
doi: 10.1186/2051-5960-1-35
pmid: 24163339
sampson2016:
authors: Sampson TR, et al.
title: Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
journal: Cell
year: 2016
doi: 10.1016/j.cell.2016.11.018
hirsch2009:
authors: Hirsch EC, Hunot S
title: 'Neuroinflammation in Parkinson''s disease: a target for neuroprotection?'
journal: Lancet Neurology
year: 2009
doi: 10.1016/S1474-4422(09)70130-4
pmid: 19592382
depboylu2012:
authors: Depboylu C, et al.
title: Deficient monocyte activation in Parkinson's disease
journal: PLoS ONE
year: 2012
doi: 10.1371/journal.pone.0011431
lawson1990:
authors: Lawson LJ, et al.
title: Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain
journal: Neuroscience
year: 1990
doi: 10.1016/0304-3940(90)90128-C
pmid: 1978681
Neuroinflammation in Parkinson's Disease describes a key molecular or cellular mechanism implicated in neurodegenerative disease, including Alzheimer's disease, dementia with lewy bodies, and multiple system atrophy. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders.
Chronic neuroinflammation is now recognized as a central pathogenic mechanism in Parkinson's disease (PD), contributing to dopaminergic neuron degeneration in the substantia nigra through multiple interconnected pathways involving microglial activation, alpha-synuclein aggregation, and mitochondrial dysfunction. Unlike acute inflammation that resolves with healing, neuroinflammation in PD becomes self-perpetuating through feed-forward loops involving microglial activation, peripheral immune infiltration, and the innate immune response to misfolded α-synuclein. This page provides a comprehensive mechanistic overview of neuroinflammatory pathways in PD and their therapeutic implications.
graph TD
subgraph "Initiation Triggers"
α["Synα-Synuclein Aggregates<br/>Fibrils, Oligomers, LB debris"]
MitoDamMicrogli["MitoDamMicroglial DAMPs<br/>mtDNA, ATP, Cardiolipin"]
PeriphPeriphera["PeriphPeripheral Inflammation<br/>LPS, Gut dysbiosis"]
NeurDeathNeuron["NeurDeathNeuronal Death<br/>Release of DAMPs"]
end
subgraph "Pattern Recognition"
T["LR2TLR2<br/>α-Syn receptor"]
T["LR4TLR4<br/>LPS + α-Syn"]
N["LRP3NLRP3 Inflammasome<br/>DAMP sensor"]
R["AGERAGE<br/>AGE + α-Syn receptor"]
end
subgraph "Microglial Response"
M1["M1 Phenotype<br/>Pro-inflammatory"]
M2["M2 Phenotype<br/>Neuroprotective"]
R["OSROS/RNS Production<br/>NO, Superoxide"]
CytokinePro-inf["CytokinePro-inflammatory Cytokines<br/>TNF-α, IL-1β, IL-6"]
PhagocytPhagocy["PhagocytPhagocytosis<br/>Impaired clearance"]
end
subgraph "Peripheral Immune"
B["BBBBB Breakdown<br/>Tight junction loss"]
TcellT["TcellT Cell Infiltration<br/>CD4+, CD8+"]
MonoMonocyte["MonoMonocyte Recruitment<br/>CCR2/CCL2 axis"]
BcellB["BcellB Cell Activation<br/>Autoantibodies"]
end
subgraph "Neuronal Damage"
NigroSNSubstant["NigroSNSubstantia Nigra<br/>Dopaminergic neurons"]
SynLossSynaptic["SynLossSynaptic Dysfunction<br/>TNF-α, IL-1β effects"]
OxiStressOxidat["OxiStressOxidative Stress<br/>ROS from microglia"]
MitochMitochond["MitochMitochondrial Damage<br/>NO inhibition of ETC"]
ApopApoptosis["ApopApoptosis<br/>Caspase activation"]
end
αSyn --> TL["R2"]
αSyn --> TL["R4"]
αSyn --> RA["GE"]
MitoDam["MitoDam"] --> NLR["P3"]
Periph["Periph"] --> TL["R4"]
NeurDeath["NeurDeath"] --> TL["R2"]
NeurDeath["NeurDeath"] --> NLR["P3"]
TL["R2"] --> M1
TL["R4"] --> M1
NLR["P3"] --> C["ytokine"]
RAGE --> M1
M1 --> R["OS"]
M1 --> C["ytokine"]
M1 -.->|Impaired in PD| P["hagocyt"]
M2 -.->|Suppressed in PD| N["igroSN"]
Periph["Periph"] --> B["BB"]
BBB --> T["cell"]
BBB --> M["ono"]
BBB --> B["cell"]
Tcell["Tcell"] --> N["igroSN"]
Mono["Mono"] --> M1
Cytokine["Cytokine"] --> S["ynLoss"]
Cytokine["Cytokine"] --> B["BB"]
ROS --> O["xiStress"]
OxiStress["OxiStress"] --> M["itoch"]
Mitoch["Mitoch"] --> A["pop"]
SynLoss["SynLoss"] --> N["igroSN"]
Apop["Apop"] --> N["eurDeath"]
Microglia exist on a spectrum of activation states rather than binary M1/M2 polarization[@heneka2018]:
Pro-inflammatory (Classical M1-like) Features:
- Morphology: Amoeboid, retracted processes
- Markers: CD68, CD86, MHC-II, iNOS
- Cytokines: TNF-α, IL-1β, IL-6, IL-12, IL-23
- Effector molecules: ROS (superoxide, H₂O₂), RNS (NO, peroxynitrite)
- Receptors: TLR2, TLR4, RAGE, P2X7
Neuroprotective (Alternative M2-like) Features:
- Morphology: Ramified, extended processes
- Markers: CD206, Arg1, Ym1, TGF-β
- Cytokines: IL-10, TGF-β
- Functions: Phagocytosis, debris clearance, trophic support
- Growth factors: BDNF, GDNF, IGF-1
PD-Specific Dysregulation:
- Chronic shift toward M1 phenotype
- Impaired M2 transition (failed resolution)
- Reduced phagocytic capacity despite activation
- Tonic (sustained) rather than phasic activation
¶ Microglial Priming and Aging
With aging, microglia become "primed" — more reactive to stimuli with impaired resolution[@streit2012]:
- Fractalkine signaling decline: Reduced CX3CR1 (microglial) / CX3CL1 (neuronal) anti-inflammatory signaling
- DAM (disease-associated microglia) phenotype: Upregulation of APOE, TREM2, CST7; downregulation of homeostatic genes (P2RY12, TMEM119)
- Senescent microglia: SASP (senescence-associated secretory phenotype) with chronic cytokine production
- Iron accumulation: Increased ferritin, labile iron pool → oxidative stress
Extracellular α-synuclein activates microglia through multiple receptors[@kim2015]:
| Receptor |
α-Syn Form |
Downstream Signaling |
Consequence |
| TLR2 |
Fibrils, oligomers |
MyD88 → NF-κB |
TNF-α, IL-1β production |
| TLR4/MD2 |
Aggregates |
MyD88/TRIF → NF-κB, IRF3 |
Pro-inflammatory cytokines |
| P2X7 |
Aggregates |
K⁺ efflux → NLRP3 |
Inflammasome activation |
| RAGE |
Oligomers |
MAPK, NF-κB |
Chronic inflammation |
| FcγR |
Antibody-bound |
ITAM → Syk |
Phagocytosis, ROS |
| LAG3 |
Fibrils |
Endocytosis |
Cell-to-cell spread |
| Integrin αMβ2 |
Fibrils |
Phagocytosis |
Internalization |
Microglial phagocytosis of α-synuclein becomes impaired in PD[@george2013]:
- Overwhelming load: Excess α-syn exceeds clearance capacity
- Autophagy dysfunction: Lysosomal degradation impaired
- Oxidative damage: Microglial ROS damage phagocytic machinery
- Age-related decline: Reduced phagocytic receptor expression
- LRRK2 mutations: Impaired autophagy in microglia (increased LRRK2 kinase activity)
The NLRP3 inflammasome is a cytosolic multiprotein complex that activates caspase-1, leading to IL-1β and IL-18 maturation[@gordon2018]:
graph LR
subgraph "Priming Signal"
T["LR_TNFTLR/NF-κB<br/>TNF-α receptor"]
N["LRP3_geneNLRP3 transcription<br/>Pro-IL-1β synthesis"]
end
subgraph "Activation Signals"
K["_effluxK⁺ Efflux<br/>P2X7, ATP, α-Syn"]
LysosomeLysosom["LysosomeLysosomal Damage<br/>α-Syn phagocytosis"]
MitoROSMitochon["MitoROSMitochondrial ROS<br/>Complex I inhibition"]
CathepsinCathep["CathepsinCathepsin B Release<br/>Lysosomal rupture"]
end
subgraph "Inflammasome Assembly"
NLRP3_sensNLRP3 S["ensor"]
A["SCASC Adaptor<br/>PYD-CARD"]
Casp1Caspase-1["Casp1Caspase-1<br/>Active tetramer"]
end
subgraph "Effectors"
I["L1bIL-1β<br/>Mature"]
I["L18IL-18<br/>Mature"]
G["SDMDGasdermin D<br/>Pore formation"]
PyroptPyroptosi["PyroptPyroptosis<br/>Inflammatory death"]
end
TLR_TNF --> NLRP3_gene
NLRP3_gene --> NLRP3_sens
K_efflux --> NLRP3_sens
Lysosome["Lysosome"] --> C["athepsin"]
Cathepsin["Cathepsin"] --> NLRP3_sens
MitoROS["MitoROS"] --> NLRP3_sens
NLRP3_sens --> A["SC"]
ASC --> C["asp1"]
Casp1["Casp1"] --> I["L1b"]
Casp1["Casp1"] --> I["L18"]
Casp1["Casp1"] --> GSD["MD"]
GSDMD --> P["yropt"]
Evidence for NLRP3 in PD:
- Elevated NLRP3, ASC, caspase-1 in PD substantia nigra
- α-Synuclein fibrils activate NLRP3 in microglia
- NLRP3-deficient mice are protected in MPTP and α-Syn models
- MCC950 (NLRP3 inhibitor) is neuroprotective in preclinical PD
Astrocytes respond to PD pathology with both protective and harmful effects[@liddelow2017]:
A1 Neurotoxic Astrocytes:
- Induced by microglial IL-1α, TNF-α, C1q
- Markers: C3, Serping1, Amigo2
- Lose neurotrophic functions (reduced GDNF, BDNF)
- Gain neurotoxic properties (complement, ROS)
- Abundant in PD substantia nigra
A2 Neuroprotective Astrocytes:
- Induced by ischemia, trauma
- Markers: S100A10, PTX3, Emp1
- Upregulate neurotrophic factors
- Promote tissue repair
PD-Specific Astrocyte Dysfunction:
- Reduced glutamate uptake (GLT-1/EAAT2 downregulation)
- Impaired metabolic support to neurons
- α-Synuclein accumulation in astrocytes
- Gap junction dysfunction (Cx43)
CD4⁺ and CD8⁺ T cells infiltrate the substantia nigra in PD[@sulzer2017]:
| T Cell Subset |
Role in PD |
Evidence |
| CD4⁺ Th1 |
Pro-inflammatory, IFN-γ |
Elevated in PD CSF |
| CD4⁺ Th17 |
Neurotoxic, IL-17 |
Correlates with severity |
| CD4⁺ Treg |
Neuroprotective, IL-10 |
Reduced in PD |
| CD8⁺ Cytotoxic |
Direct neuronal killing |
Found near dying neurons |
| γδ T cells |
Innate-like, IL-17 |
Elevated in PD blood |
α-Synuclein-Specific T Cells:
- T cells recognizing α-syn epitopes (30-50% of PD patients)
- Clonal expansion of specific TCR sequences
- May precede motor symptoms (prodromal marker)
BBB integrity is compromised in PD[@gray2051]:
- Tight junction loss: Claudin-5, occludin, ZO-1 downregulation
- Vascular inflammation: VCAM-1, ICAM-1 upregulation
- Pericyte dysfunction: Reduced coverage, PDGF-BB signaling
- MMP activation: MMP-2/9 degrade basement membrane
- Cerebral endothelial activation: NF-κB, AP-1 signaling
The gut-brain axis contributes to peripheral inflammation in PD[@sampson2016]:
- Gut dysbiosis: Altered microbiome composition, reduced SCFA-producing bacteria
- Intestinal permeability: Leaky gut → LPS translocation
- Enteric glia activation: α-Syn accumulation in ENS
- Vagal pathway: Ascending α-Syn propagation
- Peripheral LPS: Activates systemic and central inflammation
¶ Cytokines and Chemokines
| Mediator |
Cellular Source |
Target Effect |
PD Evidence |
| TNF-α |
Microglia, astrocytes |
Neuronal death, NF-κB activation |
Elevated in SN, CSF |
| IL-1β |
Microglia (inflammasome) |
Fever, endothelial activation, neurotoxicity |
Correlates with progression |
| IL-6 |
Microglia, astrocytes |
Acute phase response, T cell differentiation |
Elevated in serum |
| IFN-γ |
Th1 cells, NK cells |
MHC-II upregulation, microglial activation |
Increased in PD |
| IL-10 |
Tregs, M2 microglia |
Anti-inflammatory, tissue repair |
Reduced in PD |
| CCL2/MCP-1 |
Microglia, astrocytes |
Monocyte recruitment |
Elevated in CSF |
| CXCL10/IP-10 |
Microglia, endothelial |
T cell recruitment |
Increased in PD |
¶ Reactive Oxygen and Nitrogen Species
Microglial ROS/RNS production directly damages neurons[@hirsch2009]:
- Superoxide (O₂•⁻): NOX2 activation, mitochondrial
- Hydrogen peroxide (H₂O₂): Dismutated from superoxide
- Hydroxyl radical (•OH): Fenton chemistry with iron
- Nitric oxide (NO): iNOS induction; inhibits Complex IV
- Peroxynitrite (ONOO⁻): NO + O₂•⁻; nitrates proteins
Classical and alternative complement pathways are activated in PD[@depboylu2012]:
- C1q: Binds α-synuclein, marks synapses for removal
- C3: Opsonizes α-syn, promotes phagocytosis
- C5a: Activates microglia via C5aR1
- MAC (C5b-9): May form on neurons, sublethal damage
- Synaptic pruning: Excessive complement-mediated synapse elimination
The substantia nigra pars compacta (SNpc) is uniquely vulnerable to neuroinflammation[@lawson1990]:
| Vulnerability Factor |
Mechanism |
| High microglial density |
2x higher than other brain regions |
| Low calbindin |
Reduced calcium buffering |
| Dopamine oxidation |
Generates ROS, quinones |
| Iron accumulation |
Catalyzes Fenton chemistry |
| Neuromelanin |
Iron-binding, activates microglia |
| Complex I deficiency |
Mitochondrial ROS, DAMPs |
| α-Synuclein burden |
Chronic microglial activation |
¶ Therapeutic Targets and Strategies
| Target |
Agent |
Mechanism |
Status |
| TLR2 |
CU-CPT22, C29 |
Antagonize TLR2/TLR6 |
Preclinical |
| NLRP3 |
MCC950, Dapansutrile |
Inflammasome inhibition |
Preclinical |
| TNF-α |
Etanercept, Infliximab, XPro1595 |
TNF neutralization |
Phase II (XPro1595) |
| IL-1β |
Canakinumab, Anakinra |
IL-1β receptor blockade |
Preclinical |
| P2X7 |
JNJ-54175446 |
Antagonist |
Phase II (safety) |
| CSF1R |
PLX3397, BLZ945 |
Microglial depletion |
Preclinical (concerns) |
| TREM2 |
Antibodies |
Agonist, enhance phagocytosis |
Preclinical |
| Sphingosine-1-P |
Fingolimod |
S1P modulator, T cell sequestration |
Phase II |
Shifting M1 → M2:
- Minocycline: Inhibits microglial activation (mixed results in trials)
- Ibuprofen: NSAID with microglial effects (epidemiological protection)
- PPARγ agonists (pioglitazone): Promote M2 phenotype (Phase II negative)
Enhancing Phagocytosis:
- TREM2 agonist antibodies
- Anti-α-synuclein immunotherapy (passive/active vaccines)
- Gut microbiome: Probiotics, prebiotics, FMT
- Vagal stimulation: Reduces peripheral and central inflammation
- Exercise: Anti-inflammatory effects, increased BDNF
| Biomarker |
Sample |
Clinical Utility |
| IL-6 |
CSF, serum |
Disease progression |
| TNF-α |
CSF, serum |
Severity correlation |
| YKL-40 (CHI3L1) |
CSF |
Microglial activation |
| sTREM2 |
CSF |
Microglial activity |
| CCL2/MCP-1 |
CSF |
Monocyte recruitment |
| Neurofilament light |
Serum |
Axonal damage |
| TSPO PET |
Imaging |
Microglial activation in vivo |